Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01685021 · ClinicalTrials.gov registry record · Phase 2
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
A Phase 2 study, sponsored by MorphoSys.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01685021 is a Phase 2 study that was terminated before completion, run by MorphoSys. The registered enrollment target is 22 participants.
The verdict
NCT01685021, a Phase 2 study, was terminated before completion, sponsored by MorphoSys.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
Interventions
- DRUG MOR00208 (formerly Xmab5574)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01685021
The ClinicalTrials.gov registry entry for NCT01685021 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MorphoSys, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MOR00208 (formerly Xmab5574) is the first listed.
NCT01685021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01685021 about?
NCT01685021 is a clinical study titled "Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)". This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
What is the current status of trial NCT01685021?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2013-04. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01685021?
The interventions under investigation include: MOR00208 (formerly Xmab5574) (DRUG).
Who is sponsoring clinical trial NCT01685021?
This trial is sponsored by MorphoSys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.